Page last updated: 2024-08-17

adenosine monophosphate and Coronary Artery Disease

adenosine monophosphate has been researched along with Coronary Artery Disease in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (7.32)	29.6817
2010's	36 (87.80)	24.3611
2020's	2 (4.88)	2.80

Authors

Authors	Studies
Feng, KY; Mahaffey, KW	1
Amini, H; Azhdari Tehrani, H; Haji Aghajani, M; Moradi, O; Pourheidar, E; Rabiei, MM; Sistanizad, M	1
Abnousi, F; Bhatt, DL; Deliargyris, EN; Desai, M; Ding, VY; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Sundaram, V; White, HD; Yang, L; Yong, CM	1
Droppa, M; Geisler, T	1
Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM	1
Feih, JT; Garner Rinka, JR; Laehn, SJ; Saltzberg, MT	1
Farag, M; Gorog, DA; Gue, YX; Spinthakis, N; Srinivasan, M; Wellsted, DM	1
Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA	1
Bernardo, NL; Chen, Y; Waksman, R	1
Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Mangum, S; Olivier, CB; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilson, MD	1
Andruszkiewicz, A; Fabiszak, T; Gurbel, PA; Jeong, YH; Kozinski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM; Tantry, U	1
Price, MJ; Walsh, JA	1
Jover, E; Tello-Montoliu, A; Valdés, M	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Angiolillo, DJ; Bass, TA; Cho, JR; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM	1
Agarwal, Z; Gogo, P; Keating, FK; Schneider, DJ; Seecheran, N	1
Leonardi, S; Marino, M; Rizzotti, D	1
Gogo, P; Keating, FK; Raza, SS; Schneider, DJ; Seecheran, N	1
Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M	1
Helft, G; Montalescot, G	1
Guasti, L; Riva, N; Squizzato, A; Tamborini Permunian, E	1
Agarwal, Z; Gogo, P; Schneider, DJ; Seecheran, N	1
Schneider, DJ	1
Angiolillo, DJ; Capodanno, D	1
Bhatt, DL; Qamar, A	1
Price, MJ	1
Bhatt, DL; Croce, KJ; Faxon, DP; Leopold, JA; Mauri, L; Qamar, A; Shah, PB; Singh, A; Sobieszczyk, P; Szumita, PM; Vaduganathan, M; Venkateswaran, RV	1
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD	1
Béres, BJ; Kerecsen, G; Kiss, RG; László, A; Masszi, T; Préda, I; Tóth-Zsámboki, E; Vargová, K	1
Schneider, DJ; Sobel, BE	1
Butt, M; Lip, GY; Shantsila, E; Siddique, A	1
Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS	1
Favaloro, EJ; Franchini, M; Lippi, G	1
Ding, Z; Du, H; Guo, Y; Hu, L; Jin, J; Kunapuli, SP; Liu, J; Niu, H; Zhang, J; Zhang, S; Zhang, X; Zhang, Y	1
Bauersachs, J; Flierl, U; Kobsar, AL; Koessler, J; Pfoertsch, S; Rajkovic, MS; Rechner, AR; Schafer, A; Steigerwald, U; Walter, U	1
Angiolillo, DJ; Brtko, M; Cannon, L; Chandna, H; Dyke, C; Firstenberg, MS; Hutyra, M; Liu, T; Manoukian, SV; Montalescot, G; Prats, J; Price, MJ; Ramaiah, C; Topol, EJ; Tummala, PE; Voeltz, MD; Welsby, IJ	1
Dibattiste, PM; Ringwala, SM; Schneider, DJ	1
Bhatt, DL; Dietrich, M; Gallup, D; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; Price, MJ; Skerjanec, S; Steg, GW; Stone, GW; Todd, M; White, HD	1
Barn, K; Steinhubl, SR	1
Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Rollini, F; Tello-Montoliu, A; Tomasello, SD; Ueno, M	1

Reviews

15 review(s) available for adenosine monophosphate and Coronary Artery Disease

Article	Year
Cangrelor in clinical use. Future cardiology, 2020, Volume: 16, Issue:2 Topics: Adenosine Monophosphate; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Risk Factors; Treatment Outcome	2020
What is the Role of Cangrelor in Patients Undergoing PCI? Current vascular pharmacology, 2018, Volume: 16, Issue:5 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Coronary Artery Disease; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Treatment Outcome	2018
Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Current medical research and opinion, 2014, Volume: 30, Issue:5 Topics: Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Randomized Controlled Trials as Topic	2014
Cangrelor for treatment of arterial thrombosis. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:4 Topics: Adenosine Monophosphate; Coronary Artery Disease; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents	2014
[New antiplatelet drugs in coronary artery disease]. Medicina clinica, 2014, Dec-09, Volume: 143, Issue:11 Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX). Current cardiology reports, 2014, Volume: 16, Issue:6 Topics: Adenosine Monophosphate; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Survival Analysis; Treatment Outcome	2014
Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. Expert opinion on drug metabolism & toxicology, 2015, Volume: 11, Issue:4 Topics: Adenosine Monophosphate; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis	2015
Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists. Coronary artery disease, 2016, Volume: 27, Issue:1 Topics: Adenosine Monophosphate; Administration, Oral; Blood Platelets; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic	2016
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2016
Optimizing the Use of Cangrelor in the Real World. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017, Volume: 17, Issue:1 Topics: Adenosine Monophosphate; Animals; Clinical Trials as Topic; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis	2017
Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention. Interventional cardiology clinics, 2017, Volume: 6, Issue:1 Topics: Adenosine Monophosphate; Coronary Artery Disease; Humans; Injections, Intravenous; Percutaneous Coronary Intervention; Postoperative Complications; Purinergic P2Y Receptor Antagonists	2017
New antiplatelet drugs: beyond aspirin and clopidogrel. International journal of clinical practice, 2009, Volume: 63, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Emerging P2Y12 receptor antagonists: role in coronary artery disease. Current vascular pharmacology, 2010, Volume: 8, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor	2010
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012

Trials

10 trial(s) available for adenosine monophosphate and Coronary Artery Disease

Article	Year
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. American heart journal, 2017, Volume: 188 Topics: Adenosine Monophosphate; Administration, Oral; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticlopidine; Time Factors	2017
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor. Thrombosis and haemostasis, 2018, Volume: 118, Issue:2 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor	2018
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:4 Topics: Adenosine Monophosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Time Factors	2014
Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Vermont	2014
Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coronary artery disease, 2015, Volume: 26, Issue:1 Topics: Adenosine Monophosphate; Administration, Oral; Aged; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Time Factors; Treatment Outcome	2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3 Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome	2015
Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation. Journal of interventional cardiology, 2015, Volume: 28, Issue:5 Topics: Adenosine Monophosphate; Adult; Aged; Biological Availability; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine	2015
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA, 2012, Jan-18, Volume: 307, Issue:3 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Stents; Thienopyridines; Thrombosis	2012
Effects on platelet function of a direct acting antagonist of coagulation factor Xa. Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:3 Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Crotalid Venoms; Factor Xa; Factor Xa Inhibitors; Female; Humans; Lectins, C-Type; Male; Middle Aged; Morpholines; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rivaroxaban; Thiophenes	2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. American heart journal, 2012, Volume: 163, Issue:5 Topics: Adenosine Monophosphate; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome	2012

Other Studies

16 other study(ies) available for adenosine monophosphate and Coronary Artery Disease

Article	Year
Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19. Journal of medical virology, 2021, Volume: 93, Issue:9 Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antiviral Agents; Aspirin; Blood Platelets; Coronary Artery Disease; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Disseminated Intravascular Coagulation; Drug Combinations; Female; Hospital Mortality; Humans; Hypertension; Iran; Lopinavir; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Pulmonary Embolism; Respiration, Artificial; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Treatment Outcome	2021
Pharmacodynamic-Guided Cangrelor Bridge Therapy for Orthotopic Heart Transplant. Journal of cardiothoracic and vascular anesthesia, 2019, Volume: 33, Issue:4 Topics: Adenosine Monophosphate; Aged; Coronary Artery Disease; Heart Transplantation; Humans; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Preoperative Care	2019
Effect of P2Y Thrombosis research, 2019, Volume: 173 Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor	2019
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention. Cardiovascular revascularization medicine : including molecular interventions, 2019, Volume: 20, Issue:9 Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome	2019
intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel. Prescrire international, 2016, Volume: 25, Issue:175 Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome	2016
Cangrelor for the Rescue of Intra-Procedural Stent Thrombosis in Percutaneous Coronary Intervention. Cardiovascular revascularization medicine : including molecular interventions, 2019, Volume: 20, Issue:7 Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Female; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Treatment Outcome	2019
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circulation. Cardiovascular interventions, 2019, Volume: 12, Issue:7 Topics: Adenosine Monophosphate; Coronary Artery Disease; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2019
The arranged marriage of cangrelor and bivalirudin. JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3 Topics: Adenosine Monophosphate; Anticoagulants; Coronary Artery Disease; Female; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine	2015
Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. Journal of the American College of Cardiology, 2017, 01-31, Volume: 69, Issue:4 Topics: Adenosine Monophosphate; Aged; Coronary Artery Disease; Drug Approval; Female; Humans; Injections, Intravenous; Intraoperative Period; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Tertiary Care Centers; United States; United States Food and Drug Administration	2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:1 Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome	2017
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thrombosis and haemostasis, 2008, Volume: 100, Issue:5 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-Antagonists; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Norepinephrine; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Failure	2008
Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation. Coronary artery disease, 2009, Volume: 20, Issue:2 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Clinical Trials as Topic; Coronary Artery Disease; Crotalid Venoms; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Flow Cytometry; Heparin; Hirudins; Humans; Lectins, C-Type; P-Selectin; Peptide Fragments; Peptides; Pilot Projects; Platelet Activating Factor; Platelet Activation; Platelet Function Tests; Recombinant Proteins; Research Design; Thrombin	2009
Platelet inhibition with cangrelor. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Research Design; Ticlopidine	2010
BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thrombosis and haemostasis, 2010, Volume: 104, Issue:4 Topics: Adenine; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Blood Platelets; CHO Cells; Coronary Artery Disease; Cricetinae; Cricetulus; Humans; Mice; Mice, Knockout; Phosphoric Diester Hydrolases; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2Y12	2010
The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition. Platelets, 2011, Volume: 22, Issue:1 Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Biological Assay; Biomarkers; Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Sensitivity and Specificity; Ticlopidine; Young Adult	2011
Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. Journal of thrombosis and thrombolysis, 2013, Volume: 35, Issue:2 Topics: Adenosine Monophosphate; Aged; Coronary Artery Disease; Diabetes Complications; Female; Humans; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome	2013